Related Experiment Video
Updated: Mar 21, 2026

A Kinetic Fluorescence-based Ca2+ Mobilization Assay to Identify G Protein-coupled Receptor Agonists, Antagonists, and Allosteric Modulators
Published on: February 20, 2018
The expanding GRK interactome: Implications in cardiovascular disease and potential for therapeutic development
Jonathan Hullmann1, Christopher J Traynham2, Ryan C Coleman2
1Thomas Jefferson University, Philadelphia, PA 19107, United States.
Insights
Heart failure (HF) involves G protein-coupled receptors (GPCRs) regulated by GRK kinases. This review explores non-canonical GRK signaling in HF and potential therapies targeting GRK2 and GRK5.
Area of Science:
- Cardiovascular Biology
- Molecular Medicine
- Pharmacology
Background:
- Heart failure (HF) is a global health crisis with high mortality and morbidity.
- G protein-coupled receptors (GPCRs) are key regulators of cardiovascular function.
- GPCR kinases (GRKs) desensitize activated GPCRs; GRK2 and GRK5 are upregulated in HF.
Purpose of the Study:
- To review recent findings on non-canonical GRK signaling in heart failure.
- To present potential therapeutic strategies for targeting GRKs in HF.
Main Methods:
- Literature review of studies on GRK signaling in cardiovascular disease.
- Analysis of molecular mechanisms underlying GRK action in the failing heart.
- Evaluation of emerging therapeutic approaches for HF.
Main Results:
- GRK2 and GRK5 are critical mediators of molecular changes in the failing heart.
- Non-canonical signaling pathways of GRKs in HF are increasingly recognized.
- Emerging therapies include small molecule inhibitors, microRNAs, and gene therapy.
Conclusions:
- Understanding non-canonical GRK signaling is crucial for developing novel HF treatments.
- Targeting GRK2 and GRK5 offers promising therapeutic avenues for heart failure.
- Future research should focus on translating these findings into clinical applications.
Abstract:
Heart failure (HF) is a global epidemic with the highest degree of mortality and morbidity of any disease presently studied. G protein-coupled receptors (GPCRs) are prominent regulators of cardiovascular function. Activated GPCRs are "turned off" by GPCR kinases (GRKs) in a process known as "desensitization". GRKs 2 and 5 are highly expressed in the heart, and known to be upregulated in HF. Over the last 20 years, both GRK2 and GRK5 have been demonstrated to be critical mediators of the molecular alterations that occur in the failing heart. In the present review, we will highlight recent findings that further characterize "non-canonical" GRK signaling observed in HF. Further, we will also present potential therapeutic strategies (i.e. small molecule inhibition, microRNAs, gene therapy) that may have potential in combating the deleterious effects of GRKs in HF.
More Related Videos
08:21Monitoring GPCR-β-arrestin1/2 Interactions in Real Time Living Systems to Accelerate Drug Discovery
Published on: June 28, 2019
06:56A Flow Cytometry-based Assay to Identify Compounds That Disrupt Binding of Fluorescently-labeled CXC Chemokine Ligand 12 to CXC Chemokine Receptor 4
Published on: March 10, 2018
Related Concept Videos
Transducer Mechanism: Enzyme-Linked Receptors
Major types that are helpful drug targets include:
G Protein-coupled Receptors
GPCRs are also called heptahelical, 7TM, or serpentine receptors, and consist of seven (H1-H7) transmembrane alpha-helices that span the bilayer to form a cylindrical core. The transmembrane helices are connected by three extracellular loops and three...
G Protein-coupled Receptors
Interactions Between Signaling Pathways
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
G-Protein Gated Ion Channels
Sensory...
GPCRs Regulate Adenylyl Cylase Activity